PATENT CLAIM ANALYSIS

Application Number: 16026242
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["424", "130100"]

Abstract:
This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.

Claim (Index 21):
The isolated polypeptide of  claim 16 , wherein the antigen binding fragment of the antibody is chimeric, humanized, or a single chain antigen binding fragment.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 95.0
- Lexical Diversity: 1.74286
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13255610', '14389677', '14967167', '15501620', '14098275']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7495129469666348
- 35 USC 102 Novelty (BERT): 0.5978792266632339
- Combined Prediction Score: 0.7343495749362947
- Mean Citation Score: 426.679434
- Max Citation Score: 590.9386599999998
- Similarity Product: 406.94191975951065

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test